Key Dates

Related Announcements

• August 14, 2024 - Cancer Prevention Clinical Trials Network (CP-CTNet): CP-CTNet Sites (UG1 Clinical Trial Required). See RFA-CA-24-024
• August 14, 2024 - Cancer Prevention Clinical Trials Network (CP-CTNet): Data Management, Auditing, and Statistical Center (DMASC) (UG1 Clinical Trial Required). See RFA-CA-24-025

Issued by

National Cancer Institute (NCI)

Purpose

This notice corrects the section on Addional Information on Eligibility in NOFOs entitled “Cancer Prevention Clinical Trials Network (CP-CTNet)”: RFA-CA-24-024 and RFA-CA-24-025.

In Part 2. Full Text of Announcement, Section III. Eligibility Information, 3. Additional Information on Eligibility, for both RFA-CA-24-024 and RFA-CA-24-025:

Currently reads:

Number of Applications

Applicant organizations may submit only one application per institution

Applicant organizations may submit more than one application, provided that each application is scientifically distinct.

The NIH will not accept duplicate or highly overlapping applications under review at the same time, per NIH Grants Policy Statement Section 2.3.7.4 Submission of Resubmission Application. This means that the NIH will not accept:

• A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application.
• A resubmission (A1) application that is submitted before issuance of the summary statement from the review of the previous new (A0) application.
• An application that has substantial overlap with another application pending appeal of initial peer review (see NIH Grants Policy Statement 2.3.9.4 Similar, Essentially Identical, or Identical Applications).

Only one application per institution is allowed; the institutional resources needed to be a successful LAO and to avoid local competition for resources are too great for any one institution to be able to support more than one LAO.

Corrected to read (by deletion)

Number of Applications

Applicant organizations may submit only one application per institution

The NIH will not accept duplicate or highly overlapping applications under review at the same time, per NIH Grants Policy Statement Section 2.3.7.4 Submission of Resubmission Application. This means that the NIH will not accept:

• A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application.
• A resubmission (A1) application that is submitted before issuance of the summary statement from the review of the previous new (A0) application.
• An application that has substantial overlap with another application pending appeal of initial peer review (see NIH Grants Policy Statement 2.3.9.4 Similar, Essentially Identical, or Identical Applications).

Only one application per institution is allowed; the institutional resources needed to be a successful LAO and to avoid local competition for resources are too great for any one institution to be able to support more than one LAO.

All other aspects of RFA-CA-24-024 and RFA-CA-24-025 remain unchanged,

Inquiries

Please direct all inquiries to:

Scientific/Research Contact(s)

Eva Szabo, MD 
National Cancer Institute (NCI)
Telephone: 240-276-7011
Fax: 240-276-7848
Email: [email protected]

Peer Review Contact(s)

Referral Officer
National Cancer Institute (NCI)
Telephone: 240-276-6390
Email: [email protected]

Financial/Grants Management Contact(s)

Amy Bartosch 
National Cancer Institute (NCI) 
OFFICE OF GRANTS ADMINISTRATION  
240-276-6375 
[email protected]